Sovleplenib
Sovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC50 of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP) [1].
Product Specifications
CAS Number
1415792-84-5
Product Name Alternative
HMPL-523
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Syk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sovleplenib.html
Purity
99.94
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CS(N(CC1)CCC1C(C=C2)=CC=C2C3=CC(N=CC=N4)=C4C(NC[C@@H]5CNCCO5)=N3)(=O)=O
Molecular Formula
C24H30N6O3S
Molecular Weight
482.60
Precautions
H302, H315, H319
References & Citations
[1]Su WG, et al. Preparation of pyridopyrazine derivatives for use as Syk inhibitors. WO2012167733 A1.|[2]Na Yang, et al. HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo. Blood (2016) 128 (22) : 3970.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
